Oslo, 3 May 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a Norwegian immuno-oncology company - is pleased to
announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, today will give an oral
presentation at the 'Frontiers in Cancer Immunotherapy 2023' conference, which
is taking place in New York, USA.

Dr Rekdal has been invited by the New York Academy of Sciences to discuss how
tumor-directed strategies enable superior immune-stimulation of 'cold'
non-infiltrated tumors, in a joint presentation with Lorenzo Galluzzi, PhD,
Weill Cornell Medicine. In his presentation, Rekdal will put particular emphasis
on the efficacy data achieved in human clinical trials performed with LTX-315
and how oncolytic molecules can address the challenge represented by the modest
activity of immune checkpoint inhibitors (ICIs) in patients with immunologically
'cold' tumors. The presentation will be performed in Session 9: Cancer Vaccines,
on May 3. 

"Our technology platform delivers molecules with the potential to recruit immune
cells into the tumor microenvironment in support of strong anticancer immunity,
solving one of the major hurdles in cancer treatment. We are grateful for being
invited by the New York Academy of Sciences (NYAS) to this conference and to
present our clinical data confirming the strong pre-clinical evidence of our
proposed solution to the problem of 'cold' tumors in cancer immunotherapy", says
Dr. Øystein Rekdal.

Title: 'Clinically Viable Tumor-Directed Strategies to Enable Superior
Immunostimulation in Cold Neoplasms'
Date and time: Wednesday May 3, 2023, at 14.30-15.00 ET 

***

For more information, please contact: 
Øystein Rekdal, CEO: oystein.rekdal@lytixbiopharma.com
Ole Peter Nordby, Head of IR:   ole.peter.nordby@lytixbiopharma.com

About the Congress
Over the last 10 years, cancer immunotherapy has seen tremendous scientific
development and clinical success. The field of immuno-oncology continues to
advance at a rapid pace, with great potential to further revolutionize patient
outcomes. The conference provides an opportunity to be part of the leading forum
for scientists and clinicians to keep up with the latest trends and developments
in the field.  At the conference world-renowned leaders in the field like Nobel
Laureate Dr. James Allison (University of Texas, MD Anderson Cancer Center), Dr.
Nina Bhardwaj (Icahn School of Medicine, Mount Sinai), and Dr. Robert D.
Schreiber (Washington University School of Medicine in St. Louis) will deliver
keynote presentations. Speakers from leading biotech and life sciences companies
including Enable Medicine, Gritstone Bio, Infinity Pharmaceuticals, and Lytix
Biopharma will complement the presentations with evidence from
industrial-academic collaborations. 
https://events.nyas.org/event/b42eef99-1a18-41dc-9322-17c52d483a4a/websitePage:c
cf12eed-4b47-487c-82af-faa589df6e0a

Lytix Biopharma in brief
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior in situ therapeutic vaccination principle to boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 target cancer cells and disintegrate their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.